IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene FPGS Ensembl ENSG00000136877 Chromosome 9 Start 129604975 End 129616377
Description Folylpolyglutamate synthase, mitochondrial Precursor (EC 6.3.2.17)(Folylpoly-gamma-glutamate synthetase)(FPGS)(Tetrahydrofolylpolyglutamate synthase)(Tetrahydrofolate synthase) [Source:UniProtKB/Swiss-Prot;Acc:Q05932]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :
     HGNC : 3824
     Entrez Gene : 2356
     UCSC : uc004bsg.1
     GeneCards : 3824
     RefSeq : NM_001018078
     CCDS : CCDS35148.1
     Uniprot : Q05932
     Interpro : Q05932
     OMIM : 136510
     GeneTests : FPGS
     CGAP : FPGS

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  36923_at  0.89  1.00e-7  8.24e-7  0.59  8.45e-3  1.99e-2
 HG_U133A  202945_at  0.24  1.85e-6  4.65e-6  -1.80  1.59e-70  5.23e-70
 HG_U133_Plus2  202945_at  0.57  8.03e-7  3.69e-6  0.85  1.55e-9  6.47e-9
 Stanford  14392  -1.19  4.67e-2  1.48e-1  -1.30  2.24e-2  1.16e-1
 Agilent_HS_21.6K  9161  0.02  2.90e-1  4.78e-1  0.02  2.73e-1  4.28e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  202945_at  0.01  9.80e-1  9.99e-1  -0.12  3.80e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 36923_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 202945_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 202945_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 14392    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 9161    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
fpgs tumour In contrast with TS inhibitors such as raltitrexed, it cannot be polyglutamated, leading to antitumour activity independent of folylpolyglutamyl synthetase (FPGS) activity.The growth inhibition IC50 values for ZD9331 and raltitrexed were determined for a 12084463 Human
fpgs tumor These results show that a classical 5-deaza folate partially restricted via a bridge between the N10 and C7 positions retains FPGS substrate activity and that the antitumor activity of classical tricyclic analogues such as 3 would be influenced by FPGS le 12408727 Human
fpgs cancer The importance of folylpoly-gamma-glutamate synthetase (FPGS) in cancer chemotherapy arises from its function of adding gamma-L-glutamate moieties to classical antifolates which contain an L-glutamate. 12678736 Human
fpgs tumor For those analogs which need polyglutamylation for activation either for retention within tumor cells or to increase inhibitory activity against the target folate-dependent enzyme(s) (both of which could contribute to the antitumor activity of the analog) 12678736 Human
fpgs cancer Thus the structural requirements for substrate activity for FPGS are of critical importance in the design of classical antifolates as cancer chemotherapeutic agents. 12678736 Human
fpgs cancer This review highlights the synthesis and the structural requirement for substrate and inhibitory activity of classical antifolates for FPGS and their relevance to cancer chemotherapy. 12678736 Human
fpgs cancer Folypoly-gamma-glutamate synthetase (FPGS) is essential for the cytotoxicity of "classical" antifolates and their efficacy in cancer chemotherapy. 11309345 Human
fpgs human leukemia We have examined the mRNA expression of these FPGS splice variants in primary human leukemia cells, cell lines, and normal human hematopoietic progenitors using reverse transcription-PCR. 11309345 Human
fpgs human leukemia Folylpolyglutamate synthetase (FPGS) activity in CCRF-CEM human leukemia cells was found in the cytosolic ( approximately 67% of total) and mitochondrial ( approximately 22%) fractions. 10777604 Human
folylpolyglutamate synthetase human leukemia Folylpolyglutamate synthetase (FPGS) activity in CCRF-CEM human leukemia cells was found in the cytosolic ( approximately 67% of total) and mitochondrial ( approximately 22%) fractions. 10777604 Human
fpgs head-and-neck cancer The human K562 acute nonlymphocytic leukemia and the A253 and FaDu head and neck cancer cell lines also expressed the two FPGS isoforms, and the ratio of hcFPGS to hmFPGS protein in each cell line was similar. 10777604 Human
fpgs acute nonlymphocytic leukemia The human K562 acute nonlymphocytic leukemia and the A253 and FaDu head and neck cancer cell lines also expressed the two FPGS isoforms, and the ratio of hcFPGS to hmFPGS protein in each cell line was similar. 10777604 Human
folylpolyglutamate synthetase murine leukemia Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. 10856298 Mouse
folylpolyglutamate synthetase human leukemias Expression patterns of the multiple transcripts from the folylpolyglutamate synthetase gene in human leukemias and normal differentiated tissues. 10964921 Human
fpgs tumors Folylpoly-gamma-glutamate synthetase (FPGS) catalyzes the activation of folate antimetabolites in mammalian tissues and tumors. 10964921 Human
fpgs mouse tumor Using 5'-rapid amplification of cDNA ends, RNase protection assays, transfection of cDNAs into FPGS-deficient cells, and kinetic analysis of recombinant enzymes expressed in insect cells, it was determined that the species of active FPGS in mouse liv 10626793 Mouse
fpgs cancer The exclusive use of one of two alternative sets of initial coding exons in different tissues underlies this phenomenon, suggesting the design of antifolates specific for activation by individual FPGS isoforms and hence tissue-selective targeting of antif 10626793 Human
folylpolyglutamate synthetase human colorectal tumors Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. 10821538 Human
fpgs tumor Among tumor explants from 20 patients, FPGS expression varied over 161-fold. 10821538 Human
fpgs tumor Overall and disease-free survival data suggest an inverse association between the level of tumor TS and FPGS expression and clinical prognosis. 10821538 Human
folylpolyglutamate synthetase childhood leukemia Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. 10029597 Human
folylpolyglutamate synthetase tumors Nonpolyglutamatable antifolates are potentially of therapeutic interest for the treatment of tumors that are inherently refractory, or have become resistant, to classical antifolates as a result of decreased expression of the enzyme folylpolyglutamate syn 10101216 Human
folylpolyglutamate synthetase hepatoma Role of folylpolyglutamate synthetase in the regulation of methotrexate polyglutamate formation in H35 hepatoma cells. 2451560 Human
fpgs hepatoma The effect of culture conditions on the glutamylation of methotrexate by intact H35 hepatoma cells and folylpolyglutamate synthetase (FPGS) activity in the corresponding crude extracts has been examined. 2451560 Human
folylpolyglutamate synthetase hepatoma The effect of culture conditions on the glutamylation of methotrexate by intact H35 hepatoma cells and folylpolyglutamate synthetase (FPGS) activity in the corresponding crude extracts has been examined. 2451560 Human
fpgs human leukemia A series of folate analogs containing ornithine instead of glutamate was synthesized and tested for inhibition of folylpolyglutamate synthetase (FPGS) and other folate-dependent enzymes of human leukemia cell lines. 3190739 Human
folylpolyglutamate synthetase human leukemia A series of folate analogs containing ornithine instead of glutamate was synthesized and tested for inhibition of folylpolyglutamate synthetase (FPGS) and other folate-dependent enzymes of human leukemia cell lines. 3190739 Human
fpgs tumors Because tumors with high expression of FPGS often respond to nontoxic antifolate doses, we investigated whether augmenting tumoral FPGS activity by gene delivery would enhance tumoral antifolate sensitivity. 10413425 Human
fpgs gliosarcoma METHODS: 9L rat gliosarcoma cells were stably transfected with a human FPGS complementary DNA (cDNA), producing 9L/FPGS cells. 10413425 Human
fpgs glioblastoma In culture, enhanced antifolate sensitivity was also seen in other stably transfected rodent and human glioma cell lines, including one with high pre-existing FPGS activity, and in canine and human glioblastoma cell lines transduced with a vector bearing 10413425 Human
fpgs glioma In culture, enhanced antifolate sensitivity was also seen in other stably transfected rodent and human glioma cell lines, including one with high pre-existing FPGS activity, and in canine and human glioblastoma cell lines transduced with a vector bearing 10413425 Human
fpgs glioma CONCLUSIONS: FPGS gene delivery enhances the antifolate sensitivity of several glioma cell lines and merits further evaluation as a therapeutic strategy. 10413425 Human
folylpolyglutamate synthetase human tumor Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex) and folylpolyglutamate synthetase activity. 10477170 Human
fpgs tumor Tumor cells with a relatively high FPGS activity were more sensitive to TX cytotoxic effects and vice versa. 10477170 Human
fpgs human leukemia The aim of this study was to investigate the influence of folylpolyglutamyl synthetase (FPGS) activity on the cellular pharmacology of the classical antifolates raltitrexed and methotrexate (MTX) using two human leukemia cell lines, CCRF-CEM and CCRF-CEM: 10499632 Human
folylpolyglutamate synthetase human leukemia Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs. 10507318 Human
fpgs human leukemia We investigated the expression of the folylpolyglutamate synthetase (FPGS) gene at the mRNA level in MOLT-3 and K562 human leukemia cell lines sensitive, or made resistant, to methotrexate (MTX) and/or trimetrexate (TMQ), or raltitrexed (ZD1694). 10507318 Human
folylpolyglutamate synthetase human leukemia We investigated the expression of the folylpolyglutamate synthetase (FPGS) gene at the mRNA level in MOLT-3 and K562 human leukemia cell lines sensitive, or made resistant, to methotrexate (MTX) and/or trimetrexate (TMQ), or raltitrexed (ZD1694). 10507318 Human
fpgs tumor These results indicate that FPGS mRNA expression may predict cellular ability to produce polyglutamate metabolites of antifolate drugs in the sensitive cells, but does not necessarily reflect FPGS function at the enzyme level in the antifolate-resistant t 10507318 Human
folylpolyglutamate synthetase tumors Agents with this profile are expected to show activity against tumors that are resistant to classical antifolates due to low expression of folylpolyglutamate synthetase. 10508430 Human
fpgs tumor Total RNA was isolated from tumor tissue, reversely transcribed to cDNA and PCR amplified with primers specific for TS, FPGS and beta-actin in separate vials. 9591043 Human
fpgs acute lymphoblastic leukemia In an effort to clarify the exact mechanism of resistance to this novel TS inhibitor, we examined the molecular alterations in its target enzyme TS, the transport protein (reduced folate carrier, RFC), and folylpolyglutamate synthetase (FPGS) in a human a 9654109 Human
folylpolyglutamate synthetase acute lymphoblastic leukemia In an effort to clarify the exact mechanism of resistance to this novel TS inhibitor, we examined the molecular alterations in its target enzyme TS, the transport protein (reduced folate carrier, RFC), and folylpolyglutamate synthetase (FPGS) in a human a 9654109 Human
folylpolyglutamate synthetase human tumor METHODS: Studies were conducted with a group of human tumor cell lines in culture examining PDX and other folate analogues as permeants for mediated membrane transport, as inhibitors of dihdrofolate reductase and as substrates for folylpolyglutamate synth 9744777 Human
fpgs tumours In contrast to Tomudex (ZD1694), ZD9331 may therefore be active against tumours with low FPGS activity. 9836478 Human
fpgs human leukemia The human leukemia cell lines NALM6 (B-lineage) and CCRF/CEM (T-lineage) were used to assess potential mechanisms for these lineage differences in MTX accumulation, revealing i) greater total and long-chain MTXPG accumulation in NALM6 over a wide range of 9224825 Human
folylpolyglutamate synthetase human leukemia Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. 9242558 Human
folylpolyglutamate synthetase lymphoid leukemia In contrast to MTX, both Tomudex (Zeneca Pharmaceuticals, Wilmington, DE) and 1843U89, potent inhibitors of thymidylate synthetase, have low Kms for folylpolyglutamate synthetase, and polyglutamate forms of these inhibitors are accumulated to the same deg 9242558 Human
folylpolyglutamate synthetase acute leukemia In contrast to MTX, both Tomudex (Zeneca Pharmaceuticals, Wilmington, DE) and 1843U89, potent inhibitors of thymidylate synthetase, have low Kms for folylpolyglutamate synthetase, and polyglutamate forms of these inhibitors are accumulated to the same deg 9242558 Human
fpgs cancer Intracellular concentrations of the reduced folates (tetrahydrofolate + 5,10-methylenetetrahydrofolate) and folylpolyglutamate synthetase (FPGS) activity were determined in 14 human cancer cell lines expressing a spontaneous sensitivity to 5-FU. 9291820 Human
folylpolyglutamate synthetase cancer Intracellular concentrations of the reduced folates (tetrahydrofolate + 5,10-methylenetetrahydrofolate) and folylpolyglutamate synthetase (FPGS) activity were determined in 14 human cancer cell lines expressing a spontaneous sensitivity to 5-FU. 9291820 Human
fpgs tumours Above all, these data establish the relevance of FPGS activity for predicting the efficacy of 5-FU modulated by FA or not and point to the potential clinical interest of FPGS determination in human tumours. 9291820 Human
folylpolyglutamate synthetase acute leukemias gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. 9306433 Human
fpgs acute leukemias FPGS and GGH activities as well as the formation of total and long-chain MTX polyglutamates were measured after incubation with [3H]MTX in 15 blast samples from patients with acute leukemias (myeloid and lymphoid). 9306433 Human
fpgs myeloid leukemias Selective inhibitors of TS with a folate structure such as raltitrexed could circumvent the resistance by virtue of DHFR overproduction, and this class of compounds which have higher substrate activities for FPGS than MTX may be of value for the treatment 9479873 Human
folylpolyglutamate synthetase tumors Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. 9815719 Human
fpgs liver metastases The aim of this multicentric prospective study was to analyze the link between clinical response to FU therapy for liver metastases of colorectal carcinoma and tumoral TS and FPGS activities. 9815719 Human
fpgs colorectal carcinoma The aim of this multicentric prospective study was to analyze the link between clinical response to FU therapy for liver metastases of colorectal carcinoma and tumoral TS and FPGS activities. 9815719 Human
fpgs metastases No difference was observed between primaries and metastases for FPGS. 9815719 Human
fpgs liver metastases FPGS activity expressed in liver metastases was significantly correlated to that expressed in primaries. 9815719 Human
fpgs liver metastases However, FPGS activity measured in liver metastases was significantly higher in responsive patients (median, 1550 fmol/min/mg protein) than in nonresponsive patients (median, 1100 fmol/min/mg protein). 9815719 Human
fpgs tumor Murine FPGS contains two AUG initiation codons, shown to be responsible for mitochondrial and cytosolic forms of the enzyme in human cells [2] Previous studies indicated species, tissue, and tumor specific differences in mammalian FPGS. 8605241 Human
folylpolyglutamate synthetase cancers CB30900 is a novel, potent thymidylate synthase inhibitor which can not be polyglutamated and may be active in cancers expressing low or defective folylpolyglutamate synthetase. 8627573 Human
fpgs tumors Preliminary in vitro and clinical data have shown that the folylpolyglutamate synthetase (FPGS), the enzyme responsible for folate polyglutamylation, is another promising tool for identifying FU-FA-responsive tumors. 8740793 Human
folylpolyglutamate synthetase tumors Preliminary in vitro and clinical data have shown that the folylpolyglutamate synthetase (FPGS), the enzyme responsible for folate polyglutamylation, is another promising tool for identifying FU-FA-responsive tumors. 8740793 Human
fpgs tumors FPGS activity increased in several tumors and liver and kidney of LFD mice. 8869756 Mouse
fpgs tumors Consistent with these changes in liver FPGS, mice injected i.v. with a single dose of lometrexol accumulated significantly more drug in liver and tumors of LFD animals compared to SD mice. 8869756 Mouse
fpgs cancer These studies support the use of folic acid supplementation for cancer patients treated with antifolate therapy in order to prevent the biochemical changes in FR and FPGS associated with folate deficiency, prevent delayed toxicity to GARFT inhibitors and 8869756 Human
fpgs human leukemia Suramin is a more potent (IC50, 0.9 microM) inhibitor of FPGS partially purified from CCRF-CEM human leukemia cells than is bromosulfophthalein (IC50, 17 microM), the first reported nonsubstrate-analog inhibitor of FPGS (J. J. 8914844 Human
folylpolyglutamate synthetase human tumor Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts. 8937460 Human
fpgs tumors Activities were measured using lometrexol (6R-5,10-dideazatetrahydrofolic acid) as a substrate for FPGS with extracts of murine tissues, murine tumors, and human tumor xenografts from mice on standard diet or low folate diet. 8937460 Human
fpgs human tumor Activities were measured using lometrexol (6R-5,10-dideazatetrahydrofolic acid) as a substrate for FPGS with extracts of murine tissues, murine tumors, and human tumor xenografts from mice on standard diet or low folate diet. 8937460 Human
fpgs tumors Tissues and tumors from mice on standard diet exhibited a 6-fold range of FPGS activity. 8937460 Mouse
fpgs tumor Only the tumor with highest FPGS activity under standard diet conditions (MX-1 mammary) did not respond to low folate diet. 8937460 Human
fpgs tumor After correction for the intrinsic inhibitory activity of the parent DDATHF analog as an inhibitor of the target enzyme, the first-order rate constants for FPGS were found to be predictive of the potency of tumor cell growth inhibition for most of the com 7651366 Human
folylpolyglutamate synthetase tumor Pretreatment tumor biopsies were analyzed for TS, dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), folylpolyglutamate synthetase, and reduced folate carrier mRNA expression by real-time reverse transcription-PCR. 12576452 Human
fpgs human leukemia 7-Hydroxymethotrexate, an important metabolite of methotrexate, is a substrate for folylpolyglutamate synthetase (FPGS) isolated from rat liver and several human leukemia cell lines. 6201178 Human
folylpolyglutamate synthetase human leukemia 7-Hydroxymethotrexate, an important metabolite of methotrexate, is a substrate for folylpolyglutamate synthetase (FPGS) isolated from rat liver and several human leukemia cell lines. 6201178 Human
folylpolyglutamate synthetase tumors Folylpolyglutamate synthetase was measured in a series of mouse tissues and tumors. 6548339 Human
folylpolyglutamate synthetase hepatoma Extracts of cultured hepatocytes have approximately half the folylpolyglutamate synthetase and three times as much gamma-glutamyl hydrolase as the hepatoma cells. 3499766 Human
fpgs tumor There was some correlation between FPGS substrate activity and the potency of folate antimetabolites as cytotoxic compounds but not necessarily as compounds selectively cytotoxic to tumor cells. 2448651 Human
folylpolyglutamate synthetase cancer Folate analog nonsubstrates and inhibitors of folylpolyglutamate synthetase as potential cancer chemotherapy drugs. 2448652 Human
folylpolyglutamate synthetase tumor Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain. 2871191 Human
fpgs sarcoma 180 Folylpolyglutamyl synthetase (FPGS), partially purified from murine L1210 leukemia and Sarcoma 180 cells and the proliferative fraction of luminal epithelium from mouse small intestine (the site of limiting toxicity to folate analogues), was examined for 2369741 Mouse
fpgs tumor For FPGS derived from proliferative intestinal epithelium, aminopterin was also the preferred substrate, but the value for Vmax (derived with crude cell-free extract) was 6-fold lower than for tumor cell FPGS. 2369741 Mouse
fpgs tumor The value for Km derived with aminopterin was similar to that derived for either tumor cell FPGS. 2369741 Mouse
fpgs human leukemia NaHCO3 activated the folylpolyglutamate synthetase (FPGS) from rat liver and the human leukemia cell lines K562 and CCRF-CEM by 1.7- to 2.0-fold. 2168155 Human
folylpolyglutamate synthetase human leukemia NaHCO3 activated the folylpolyglutamate synthetase (FPGS) from rat liver and the human leukemia cell lines K562 and CCRF-CEM by 1.7- to 2.0-fold. 2168155 Human
fpgs tumor These results derived from an in vivo tumor model provide further evidence for a role of FPGS as a determinant of cytotoxicity and acquired resistance to classical folate analogs. 2206778 Mouse
fpgs colon cancer Altogether, these results indicate that resistance to Pemetrexed in the colon cancer cell line WiDr was solely due to upregulation of TS of which all related parameters (mRNA and protein expression and TS activity) were increased, rather than alterations 12907242 Human
folylpolyglutamate synthetase colon tumor Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. 8527866 Human
fpgs tumor The assay was applied to measure the activity of FPGS in several cancer cell lines and human and murine (tumor) tissues. 8527866 Human
fpgs cancer The assay was applied to measure the activity of FPGS in several cancer cell lines and human and murine (tumor) tissues. 8527866 Human
fpgs colon tumors Murine gut mucosa had a very low FPGS activity compared to murine liver (7 vs. 24 pmol diglutamate/h/g wet weight), but the activity in murine colon tumors was comparable to or higher than that in liver (28-52 pmol diglutamate/h/g wet weight). 8527866 Mouse
fpgs tumor A screening of 11 human colon tumors or metastases demonstrated that there was a large variation in FPGS activity in this tumor type, but overall the activity was higher in tumor tissue than in normal colon mucosa. 8527866 Human
fpgs metastases A screening of 11 human colon tumors or metastases demonstrated that there was a large variation in FPGS activity in this tumor type, but overall the activity was higher in tumor tissue than in normal colon mucosa. 8527866 Human
fpgs human colon tumors A screening of 11 human colon tumors or metastases demonstrated that there was a large variation in FPGS activity in this tumor type, but overall the activity was higher in tumor tissue than in normal colon mucosa. 8527866 Human
folylpolyglutamate synthetase tumors By eliminating the need for polyglutamation, this class of antifolates may have clinical activity in the treatment of solid tumors expressing low levels of folylpolyglutamate synthetase or tumors resistant to antifolate therapy due to increased gamma-glut 8313357 Human
fpgs tumor The excellent combination of TS inhibitory activity, FPGS substrate activity, and affinity for the reduced folate transport system in the most potent of these derivatives, 3e, resulted in IC50 values of 0.2-0.8 nM against these tumor lines. 8145235 Human
folylpolyglutamate synthetase tumor The compounds were tested as inhibitors of methotrexate uptake as a measure of binding to the reduced folate transport system, as inhibitors of glycinamide ribonucleotide transformylase, as substrates for folylpolyglutamate synthetase, and as inhibitors o 8027993 Human
fpgs lymphoblastic leukemia The mechanism of action of TNP-351 was evaluated using some methotrexate-resistant CCRF-CEM human lymphoblastic leukemia cell lines as well as partially purified enzymes folylpolyglutamate synthetase (FPGS), aminoimidazolecarboxamide ribonucleotide transf 8033293 Human
folylpolyglutamate synthetase lymphoblastic leukemia The mechanism of action of TNP-351 was evaluated using some methotrexate-resistant CCRF-CEM human lymphoblastic leukemia cell lines as well as partially purified enzymes folylpolyglutamate synthetase (FPGS), aminoimidazolecarboxamide ribonucleotide transf 8033293 Human
folylpolyglutamate synthetase tumor Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. 7865908 Human
fpgs tumor To facilitate investigations regarding the association between FPGS content of tumor tissues and the sensitivity of tumors to antifolates, we developed a polymerase chain reaction (PCR)-based gene expression quantitation assay for measuring relative amoun 7865908 Human
fpgs tumors To facilitate investigations regarding the association between FPGS content of tumor tissues and the sensitivity of tumors to antifolates, we developed a polymerase chain reaction (PCR)-based gene expression quantitation assay for measuring relative amoun 7865908 Human
fpgs acute myelogenous leukemia Among leukemic cells from 11 acute lymphocytic leukemia and acute myelogenous leukemia patients, FPGS expression varied by over 500-fold.(ABSTRACT TRUNCATED AT 250 WORDS) 7865908 Human
fpgs acute-lymphocytic leukemia Among leukemic cells from 11 acute lymphocytic leukemia and acute myelogenous leukemia patients, FPGS expression varied by over 500-fold.(ABSTRACT TRUNCATED AT 250 WORDS) 7865908 Human
fpgs tumor OBJECTIVE: The enzyme folylpolyglutamyl synthetase (FPGS) is involved in the resistance to methotrexate in tumor cell lines. 12673886 Human
folylpolyglutamate synthetase tumor The most potent compounds had Ki values as low as 2.5 nM against the human enzyme, were good substrates for the cellular reduced folate transport system and for folylpolyglutamate synthetase, and had IC50 values for growth inhibition of tumor cell lines a 8230138 Human
fpgs human leukemia CCRF-CEM human leukemia sublines resistant to short-term methotrexate (MTX) exposure as a result of decreased folylpolyglutamate synthetase (FPGS) activity were examined for their response to other cytotoxic agents. 8255099 Human
folylpolyglutamate synthetase human leukemia CCRF-CEM human leukemia sublines resistant to short-term methotrexate (MTX) exposure as a result of decreased folylpolyglutamate synthetase (FPGS) activity were examined for their response to other cytotoxic agents. 8255099 Human
folylpolyglutamate synthetase tumor The compounds were tested as inhibitors of methotrexate uptake as a measure of binding to the reduced folate transport system, as inhibitors of glycinamide ribonucleotide transformylase, as substrates for folylpolyglutamate synthetase, and as inhibitors o 1573633 Human
fpgs acute lymphoblastic leukemia In striking contrast, substantial levels of FPGS were found in circulating lymphoblasts from eight patients with acute lymphoblastic leukemia. 1435744 Human
fpgs acute lymphoblastic leukemias The levels of FPGS found in these transformed stem cells would help to explain the sensitivity of many acute lymphoblastic leukemias to folate antimetabolites. 1435744 Human
folylpolyglutamate synthetase squamous carcinoma Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. 1450491 Human
folylpolyglutamate synthetase squamous carcinoma The activity of folylpolyglutamate synthetase was measured in extracts of head and neck squamous carcinoma cell lines and in surgical specimens utilizing a new rapid method to separate free [3H]glutamate from [3H]glutamate incorporated into methotrexate, 1450491 Human
folylpolyglutamate synthetase tumor In nine head and neck tumor biopsies, a broad range in activity of folylpolyglutamate synthetase was observed (25-1827 pmol/mg/hr) which partly overlapped the enzyme activity in 'normal' tissue (7-297 pmol/mg/hr). 1450491 Human
folylpolyglutamate synthetase tumor For six patients, folylpolyglutamate synthetase was measured in the center of the tumor, in the transitional region from tumor to 'normal' tissue, and in the 'normal' tissue. 1450491 Human
folylpolyglutamate synthetase head-and-neck cancer The results of this study provide further support for the concept that putative differences in folylpolyglutamate synthetase activity between tumor tissue and normal tissue can be exploited to improve the effectiveness of antifolate-based chemotherapy in 1450491 Human
folylpolyglutamate synthetase tumor The results of this study provide further support for the concept that putative differences in folylpolyglutamate synthetase activity between tumor tissue and normal tissue can be exploited to improve the effectiveness of antifolate-based chemotherapy in 1450491 Human
fpgs human leukemia None of these compounds were metabolized to the respective polyglutamate derivative as judged by their inability to serve as substrates for CCRF-CEM human leukemia cell folylpolyglutamate synthetase (FPGS) in vitro. 1992121 Human
folylpolyglutamate synthetase human leukemia None of these compounds were metabolized to the respective polyglutamate derivative as judged by their inability to serve as substrates for CCRF-CEM human leukemia cell folylpolyglutamate synthetase (FPGS) in vitro. 1992121 Human
folylpolyglutamate synthetase human leukemia Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. 2007575 Human
fpgs tumors Polyglutamation may therefore act as an almost essential activation step and ICI D1694 may be highly specific for tumors expressing both the reduced-folate carrier and FPGS. 1877386 Human
fpgs tumor RT-PCR analysis for the expression of genes involved in folate metabolism demonstrated that increased sensitivity to PDX correlated with higher RFC-1 gene expression with no difference in FPGS or FPGH levels, suggesting that measurement of tumor RFC-1 gen 12854905 Human
folylpolyglutamate synthase primary colorectal cancer EXPERIMENTAL DESIGN: Real-time PCR was used to quantify expression levels of folate-associated genes including the reduced folate carrier (RFC-1), folylpolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH),and thymidylate synthase (TS) in tumor ti 14676127 Human
folylpolyglutamate synthase tumor EXPERIMENTAL DESIGN: Real-time PCR was used to quantify expression levels of folate-associated genes including the reduced folate carrier (RFC-1), folylpolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH),and thymidylate synthase (TS) in tumor ti 14676127 Human
folylpolyglutamate synthase colorectal carcinoma Low expression of reduced folate carrier-1 and folylpolyglutamate synthase correlates with lack of a deleted in colorectal carcinoma mRNA splice variant in normal-appearing mucosa of colorectal carcinoma patients. 16122883 Human
fpgs t-all The ratio of (DHFR x FPGH)/(RFC x FPGS) was more discriminating between T-ALL and c/preB-ALL (eight-fold higher; P < 0.001) than either target independently. 11187907 Human
fpgs aml The ratio of FPGH/FPGS was more discriminating between AML and c/preB-ALL (four-fold higher; P = 0.001) than either target independently. 11187907 Human
fpgs t-all We analyzed the profile of MTX polyglutamylation in childhood c/preB-ALL, T-ALL, and AML (n = 45, 15, and 14, respectively), the activity of the MTX-polyglutamate synthesizing enzyme folylpolyglutamate synthetase (FPGS) (n = 39, 11, and 19, respectively) 10029597 Human
fpgs aml We analyzed the profile of MTX polyglutamylation in childhood c/preB-ALL, T-ALL, and AML (n = 45, 15, and 14, respectively), the activity of the MTX-polyglutamate synthesizing enzyme folylpolyglutamate synthetase (FPGS) (n = 39, 11, and 19, respectively) 10029597 Human
fpgs t-all The FPGS activity was twofold lower in T-ALL and AML than in c/preB-ALL samples (P <. 01). 10029597 Human
fpgs aml The FPGS activity was twofold lower in T-ALL and AML than in c/preB-ALL samples (P <. 01). 10029597 Human
fpgs t-all In conclusion, low FPGS activity is associated with low accumulation of MTX-Glu4-6 in T-ALL and AML. 10029597 Human
fpgs aml In conclusion, low FPGS activity is associated with low accumulation of MTX-Glu4-6 in T-ALL and AML. 10029597 Human
fpgs human tumour In contrast with TS inhibitors such as raltitrexed, it cannot be polyglutamated, leading to antitumour activity independent of folylpolyglutamyl synthetase (FPGS) activity.The growth inhibition IC50 values for ZD9331 and raltitrexed were determined for a 12084463 Human
fpgs primary colorectal cancer EXPERIMENTAL DESIGN: Real-time PCR was used to quantify expression levels of folate-associated genes including the reduced folate carrier (RFC-1), folylpolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH),and thymidylate synthase (TS) in tumor ti 14676127 Human
fpgs tumor EXPERIMENTAL DESIGN: Real-time PCR was used to quantify expression levels of folate-associated genes including the reduced folate carrier (RFC-1), folylpolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH),and thymidylate synthase (TS) in tumor ti 14676127 Human
fpgs tumor RESULTS: Mean gene expression levels of RFC-1, FPGS, GGH, and TS were significantly higher in tumor biopsies compared with mucosa. 14676127 Human
fpgs tumor Univariate and multivariate analyses showed that the FPGS gene expression level in mucosa, but not in tumor, was a prognostic parameter independent of the clinicopathological factors with regard to survival. 14676127 Human
fpgs tumor CONCLUSION: Our results suggest that normal-appearing colonic mucosa adjacent to primary colon cancer can show altered gene expression levels of FPGS that may have bearing on the development of aggressive metastatic behavior of the tumor and on tumor-spec 14676127 Human
fpgs primary colon cancer CONCLUSION: Our results suggest that normal-appearing colonic mucosa adjacent to primary colon cancer can show altered gene expression levels of FPGS that may have bearing on the development of aggressive metastatic behavior of the tumor and on tumor-spec 14676127 Human
fpgs colon cancer AIM: We investigated the effects of FPGS modulation on the chemosensitivity of colon cancer cells to 5-FU and MTX. 15542523 Human
fpgs colon cancer METHODS: Human HCT116 colon cancer cells were stably transfected with the sense or antisense FPGS cDNA or blank (control). 15542523 Human
fpgs colon cancer CONCLUSIONS: These data provide functional evidence that FPGS overexpression and inhibition modulate chemosensitivity of colon cancer cells to 5-FU by altering intracellular folate polyglutamylation, providing proof of principle. 15542523 Human
fpgs colon cancer Thus FPGS status may be an important predictor of chemosensitivity of colon cancer cells to 5-FU based chemotherapy, and FPGS gene transfer may increase the sensitivity of colon cancer cells to 5-FU-based chemotherapy. 15542523 Human
fpgs tumor For 11 of these same genes (FPGS, DHFR, GGH, NME1, NME2, RRM2, UMPH2, UNG, UMPS, TP53, and TK1), a significant proportion of the patients showed an over expression of the particular gene in tumor tissue with a tumor-to-nonmalignant (T/N) ratio >1.2, where 15814641 Human
fpgs tumor Extension of the bridge homologation studies of classical two-carbon bridged antifolates, a 5-substituted 2,4-diaminofuro[2,3-d]pyrimidine (1) and a 6-subsituted 2-amino-4-oxopyrrolo[2,3-d]pyrimidine (2), afforded two four-carbon bridged antifolates, anal 16078850 Human
folylpolyglutamate synthetase head and neck tumor In nine head and neck tumor biopsies, a broad range in activity of folylpolyglutamate synthetase was observed (25-1827 pmol/mg/hr) which partly overlapped the enzyme activity in 'normal' tissue (7-297 pmol/mg/hr). 1450491 Human
folylpolyglutamate synthetase solid tumors By eliminating the need for polyglutamation, this class of antifolates may have clinical activity in the treatment of solid tumors expressing low levels of folylpolyglutamate synthetase or tumors resistant to antifolate therapy due to increased gamma-glut 8313357 Human
folylpolyglutamate synthetase cancer A number of biochemical mechanisms of resistance have been proposed and for the drugs to be activated in cancer cells impairment of activation enzymes were reported as one of the mechanisms; for example, deoxycytidine kinase for cytarabine and gemcitabine 9155149 Human
folylpolyglutamate synthetase t-all We analyzed the profile of MTX polyglutamylation in childhood c/preB-ALL, T-ALL, and AML (n = 45, 15, and 14, respectively), the activity of the MTX-polyglutamate synthesizing enzyme folylpolyglutamate synthetase (FPGS) (n = 39, 11, and 19, respectively) 10029597 Human
folylpolyglutamate synthetase aml We analyzed the profile of MTX polyglutamylation in childhood c/preB-ALL, T-ALL, and AML (n = 45, 15, and 14, respectively), the activity of the MTX-polyglutamate synthesizing enzyme folylpolyglutamate synthetase (FPGS) (n = 39, 11, and 19, respectively) 10029597 Human
folylpolyglutamate synthetase colon cancer Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. 15542523 Human
folylpolyglutamate synthetase head and neck cancer The results of this study provide further support for the concept that putative differences in folylpolyglutamate synthetase activity between tumor tissue and normal tissue can be exploited to improve the effectiveness of antifolate-based chemotherapy in 1450491 Human
fpgs all We determined the expression of FPGS activity in blasts from children with ALL at diagnosis and after treatment with MTX as a single agent, before conventional remission induction therapy. 7517720 Human
fpgs all Comparable lineage differences in normal lymphoid versus nonlymphoid cells suggest a lineage-specific control of FPGS expression, FPGS activity increased in ALL blasts after in vivo exposure to MTX. 7517720 Human
fpgs all The median increase in FPGS activity was significantly higher (P = .003) in B-lineage ALL (188%) than in T-lineage ALL (37%). 7517720 Human
fpgs all Likewise, the percentage of intracellular long chain MTX-PG (Glu3-6) was significantly higher (P = .02) in B-lineage ALL (92%) than in T-lineage ALL (65%), consistent with higher FPGS activity in B-lineage blasts. 7517720 Human
fpgs acute lymphocytic leukemia Among leukemic cells from 11 acute lymphocytic leukemia and acute myelogenous leukemia patients, FPGS expression varied by over 500-fold.(ABSTRACT TRUNCATED AT 250 WORDS) 7865908 Human
fpgs tumors FPGS RNA transcripts incorporating exons A1a and A1b were detected in both normal mouse tissues, particularly, liver and kidney, and also to a varying extent in tumors; FPGS RNA transcripts incorporating exons B1a, B1b, and B1c were detected mainly in tum 9038166 Mouse
fpgs all There was a significant relationship between FPGS mRNA and enzyme activity in lymphoblasts from children with newly diagnosed ALL, and blast FPGS mRNA and activity increased after methotrexate treatment. 9224825 Human
fpgs human tumours Above all, these data establish the relevance of FPGS activity for predicting the efficacy of 5-FU modulated by FA or not and point to the potential clinical interest of FPGS determination in human tumours. 9291820 Human
fpgs head and neck cancer The human K562 acute nonlymphocytic leukemia and the A253 and FaDu head and neck cancer cell lines also expressed the two FPGS isoforms, and the ratio of hcFPGS to hmFPGS protein in each cell line was similar. 10777604 Human
fpgs acute myeloid leukemia (aml) Acute myeloid leukemia (AML) cells, considered MTX resistant, expressed two-fold lower levels of FPGS mRNA compared to c/preB-ALL (P = 0.04). 11187907 Human
fpgs ovarian tumour Thus, ZD9331 overcomes resistance to raltitrexed in ovarian tumour cell lines expressing low levels of FPGS. 12084463 Human
fpgs all The observed median concentrations of total MTXPG at 44 h was higher in B-lineage than in T-cell ALL (1706 vs 518 pmol/10(9) cells, P<0.025), consistent with the higher estimated Vmax for FPGS activity in B-lineage vs T-lineage blasts (414 vs 93 pmol/10(9 12439601 Human
fpgs all We found significantly lower expression of the reduced folate carrier (SLC19A1, an MTX uptake transporter) in E2A-PBX1 ALL, significantly higher expression of breast cancer resistance protein (ABCG2, an MTX efflux transporter) in TEL-AML1 ALL, and lower e 15630450 Human
folylpolyglutamate synthase sarcoma Much lower Km values for D1694 and 1843U89 as compared to MTX for folylpolyglutamate synthase were measured in the sarcoma cell lines, with Vmax values equal to or slightly higher than those obtained with MTX. 9816025 Human
fpgs t-lineage acute lymphoblastic leukemia (t-all) T-lineage acute lymphoblastic leukemia (T-ALL), relatively MTX resistant compared to common/preB-ALL, displayed higher mRNA levels of DHFR and TS (three- and four-fold higher, respectively; P < 0.001), while FPGS expression was lower (three-fold, P = 0.00 11187907 Human
fpgs t-all In this report, we investigated the molecular regulatory mechanisms directing FPGS gene expression in Bp-ALL and T-ALL cells. 16707018 Human
fpgs t-all CCRF-CEM cells indicating that differences in transcription rate led to the observed lineage differences in FPGS expression between Bp-ALL and T-ALL blasts. 16707018 Human
folylpolyglutamate synthetase leukemia Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. 7517720 Human
folylpolyglutamate synthetase leukemia Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. 7865908 Human
folylpolyglutamate synthetase human leukemia Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. 8255099 Human
folylpolyglutamate synthetase human leukemia Studies on the cross resistance of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. 8304203 Human
folylpolyglutamate synthetase leukemia The major difference found between leukemia cells that accumulate long chain polyglutamates and those that do not were differences in Km values for the enzyme folylpolyglutamate synthetase. 9242558 Human
fpgs leukemia Here we describe the cloning of a cDNA encoding murine FPGS isolated from L1210 leukemia cells. 8605241 Mouse
fpgs leukemia To initiate an understanding of these interacting levels of control, we have determined the position and properties of the minimal FPGS promoter controlling transcription of the FPGS gene in human CEM leukemia cells, a line which expresses high levels of 9312158 Human
fpgs leukemia The effect of down-regulation of folylpoly-gamma-glutamate synthetase (FPGS) activity on intracellular reduced folate accumulation and cellular proliferation was examined, using an inducible antisense expression system in the human T-lymphoblastic leukemi 9714324 Human
fpgs leukemia FPGS expression in the MTX-sensitive human T-lymphoblastic leukemia cell line CCRF-CEM and a number of MTX-resistant sublines was previously investigated at the DNA, RNA, and activity levels. 9778690 Human
fpgs hnscc In these last 3 cell lines, the mechanism of resistance was not correlated with altered membrane transport of MTX or changes in dihydrofolate reductase activity, but rather was associated with a 3-fold lower activity of intracellular folylpolyglutamate sy 1639538 Human
fpgs hnscc These results indicate that antifolate membrane transport and intracellular FPGS activity are important factors in determining sensitivity or resistance of HNSCC cells to short-term antifolate compound exposures. 1639538 Human
fpgs leukemia Folylpolyglutamyl synthetase (FPGS), partially purified from murine L1210 leukemia and Sarcoma 180 cells and the proliferative fraction of luminal epithelium from mouse small intestine (the site of limiting toxicity to folate analogues), was examined for 2369741 Mouse
folylpolyglutamate synthase hnscc In these last 3 cell lines, the mechanism of resistance was not correlated with altered membrane transport of MTX or changes in dihydrofolate reductase activity, but rather was associated with a 3-fold lower activity of intracellular folylpolyglutamate sy 1639538 Human
folylpolyglutamate synthetase leukemia Submitochondrial localization of the mitochondrial isoform of folylpolyglutamate synthetase in CCRF-CEM human T-lymphoblastic leukemia cells. 16169100 Human
fpgs leukemia The sensitivity of model cells, expressing a range of FPGS activities similar to that observed in leukemia blasts, to MTX varied over four orders of magnitude. 10470377 Human
fpgs tumor Thus, alkylation of the C9 position in the C8-C9 bridge of the classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidine is highly conducive to DHFR and tumor inhibitory activity as well as FPGS substrate efficiency. 11960504 Human
fpgs human leukemia Compound 13 is a poor inhibitor of purified DHFR and TS, and both 13 and 14 are poor inhibitors of the growth of CCRF-CEM human leukemia cells in culture, indicating that single carbon bridged compounds in these series though conducive to FPGS substrate a 16990006 Human
folylpolyglutamate synthetase tumor Best response rates and median time to tumor progression for high versus low thymidine phosphorylase expression were 27.6% versus 6.3% (P = 0.023) and 5.4 versus 1.9 months (P = 0.076), and for folylpolyglutamate synthetase were 37.5% versus 10.0% (P = 0. 17575230 Human
fpgs all BACKGROUND: Expression of folylpoly-gamma-glutamate synthetase (FPGS) gene is two- to three-fold higher in B-precursor ALL (Bp- ALL) than in T-lineage ALL (T-ALL) and correlates with intracellular accumulation of methotrexate (MTX) polyglutamates and lymp 16707018 Human
fpgs t-all BACKGROUND: Expression of folylpoly-gamma-glutamate synthetase (FPGS) gene is two- to three-fold higher in B-precursor ALL (Bp- ALL) than in T-lineage ALL (T-ALL) and correlates with intracellular accumulation of methotrexate (MTX) polyglutamates and lymp 16707018 NA
fpgs t-all METHODS: To determine FPGS transcription rate in Bp-ALL and T-ALL we used nuclear run-on assays. 16707018 NA
fpgs nhl We observed a decreased risk of NHL over-all with BHMTEx8+453A>T and increased risk with CBS Ex13+41C>T, FPGS Ex15-263T>C, and SHMT1 Ex12+138C>T and Ex12+236C>T. 17119116 Human
fpgs tumor A major mechanism of tumor resistance to clinically useful antifolates is based on their need for polyglutamylation via the enzyme folylpoly-gamma-glutamate synthetase (FPGS). 17896913 Human
fpgs tumor The recognition of both the native and denatured conformations of FPGS by these MAbs should provide useful reagents for FPGS quantitation in either tumor cell lysates or in tumor biopsies. 17600497 Human
fpgs cancer These observations suggest that genetic variations in FPGS may alter the efficacy of antifolate therapy in cancer patients. 17875718 Human
fpgs cancer FPGS modulation affects the chemosensitivity of cancer cells to antifolates, such as methotrexate, and 5-fluorouracil (5FU) by altering polyglutamylation of antifolates and specific target intracellular folate cofactors. 18025275 Human
fpgs breast cancer We generated an in vitro model of FPGS overexpression and inhibition in breast cancer cells by stably transfecting human MDA-MB-435 breast cancer cells with the sense FPGS cDNA or FPGS-targeted small interfering RNA, respectively, and investigated the eff 18025275 Human
fpgs breast cancer FPGS modulation-induced changes in polyglutamylation of both antifolates and folate cofactors and in intracellular folate pools affected chemosensitivity of breast cancer cells to pemetrexed and trimetrexate whose cytotoxic effects do or do not depend on 18025275 Human
fpgs breast cancer However, the effects of FPGS modulation on the chemosensitivity of breast cancer cells to 5FU and methotrexate seem to be highly complex and depend not only on polyglutamylation of a specific target intracellular folate cofactor or methotrexate, respectiv 18025275 Human
fpgs breast cancer Whether or not FPGS modulation may be an important clinical determinant of chemosensitivity of breast cancer cells to 5FU and methotrexate-based chemotherapy needs further exploration. 18025275 Human
fpgs tumors These results suggest that FPGS and GGH expression levels in tumors are determinants of the efficacy of LV in enhancing the antitumor activity of 5-FU. 18035049 Human
fpgs tumor The gene expression levels of thymidylate synthase (TS), reduced folate carrier (RFC-1), folylpolyglutamate synthase (FPGS), and methylenetetrahydrofolate reductase (MTHFR) in mucosa and tumor were compared with patients with MSS. 18039426 Human
fpgs tumor Gene expression levels of TS, RFC-1, FPGS, and MTHFR in mucosa and tumors were quantified and the difference in TS expression between tumor and mucosa was designated DeltaTS. 18039426 Human
fpgs tumors Gene expression levels of TS, RFC-1, FPGS, and MTHFR in mucosa and tumors were quantified and the difference in TS expression between tumor and mucosa was designated DeltaTS. 18039426 Human
fpgs tumors Gene expression of TS and FPGS were significantly higher in right-sided MSI-H tumors compared with right-sided MSS/MSI-L tumors (P < .0001, P = .041, respectively). 18039426 Human
fpgs tumor A major mechanism of tumor resistance to clinically useful antifolates is based on their need for polyglutamylation via the enzyme folylpoly-gamma-glutamate synthetase (FPGS). 18288923 Human
fpgs colorectal cancer (crc) Low gene expression of folylpolyglutamate synthase (FPGS) in colorectal mucosa correlates with low folate levels and poor survival of colorectal cancer (CRC) patients. 18418463 Human
folylpolyglutamate synthase tumor The gene expression levels of thymidylate synthase (TS), reduced folate carrier (RFC-1), folylpolyglutamate synthase (FPGS), and methylenetetrahydrofolate reductase (MTHFR) in mucosa and tumor were compared with patients with MSS. 18039426 Human
folylpolyglutamate synthase colorectal cancer (crc) Low gene expression of folylpolyglutamate synthase (FPGS) in colorectal mucosa correlates with low folate levels and poor survival of colorectal cancer (CRC) patients. 18418463 Human
fpgs colorectal cancer Low gene expression of folylpolyglutamate synthase (FPGS) in colorectal mucosa correlates with low folate levels and poor survival of colorectal cancer (CRC) patients. 18418463 Human
folylpolyglutamate synthase colorectal cancer Low gene expression of folylpolyglutamate synthase (FPGS) in colorectal mucosa correlates with low folate levels and poor survival of colorectal cancer (CRC) patients. 18418463 Human
folylpolyglutamate synthase liver metastases Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), me 18676755 Human
folylpolyglutamate synthase primary tumors Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), me 18676755 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.